Study S002749

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study Assessing the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes Mellitus.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07755150
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 272
Start: 2026-08-30
Primary completion: 2027-10-20
Lead sponsor: Chendu DIAO Pharmaceutical Group CO., LTD.
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:DA-302168S; DRUG:Placebo of DA-302168S
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change from baseline in HbA1c [From baseline (week 1) to week 16]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.